ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Papillomavirus Recombinant Vaccine nonavalent

Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.

Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.

Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 21, 200925 company-led studies, 10 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only207 open or runningphase 3since Jul 21, 2009Jul 21, 2009Jan 15, 2027phase 3 · NCT04199689
Shanghai Bovax Biotechnologyits history only21 open or runningphase 3since Jun 8, 2020Jun 8, 2020none ahead
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only11 open or runningearly phase 1since Apr 28, 2025Apr 28, 2025none ahead
Takeda10 open or runningphase 3since Mar 16, 2020Mar 16, 2020none ahead
Xiamen Innovax Biotechits history only11 open or runningphase 4since Jun 16, 2026Jun 16, 2026Feb 28, 2027phase 4 · NCT07668271

Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2020First study: phase 3 study in DengueFirst studyNCT04313244 · 614 enrolled · Thailand

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

The one study Takeda leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04313244Dengue · Thailand3CompletedFeb 21, 2022614

How it is read

Names in the registry

  • “V503”, 10 entries
  • “9vHPV Vaccine”, 5 entries
  • “9vHPV vaccine”, 5 entries
  • “9-valent HPV vaccine (Cecolin 9)”, 1 entry
  • “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.